転移性大腸がんの世界市場-2023年～2030年

概要

転移性大腸がんの世界市場は2022年に34億米ドルに達し、2023-2030年の予測期間中にCAGR 4.6%で成長し、2030年には48億米ドルに達すると予測されます。転移性大腸がん市場は、罹患率や有病率の増加、研究開発活動の活発化、政府のイニシアティブなどの要因によって牽引されています。

遺伝的変数、腫瘍微小環境との相互作用、その他の外的要因のすべてが大腸転移に関与しています。転移性大腸がん（mCRC）の治療には、全身化学療法、標的療法、免疫療法の3種類の治療法が用いられます。

市場力学

転移性大腸がん治療に対するFDA承認の増加が世界の転移性大腸がん市場の成長を牽引

2023年1月、フルオロピリミジン、オキサリプラチン、イリノテカンをベースとした化学療法を受けた後に進行したRAS野生型HER2陽性の転移性または切除不能大腸がんの治療薬として、ツカチニブ（Tukysa、Seagen Inc.）とトラスツズマブが食品医薬品局（FDA）から加速承認を取得しました。MOUNTAINEER（NCT03043313）と呼ばれる非盲検の多施設共同実験では、84人の患者で有効性が検討されました。

患者は、HER2陽性、RAS野生型、切除不能または転移性の大腸がんに対して、過去にフルオロピリミジン、オキサリプラチン、イリノテカン、抗血管内皮増殖因子（VEGF）モノクローナル抗体（mAb）による治療を受けていました。抗プログラム細胞死プロテイン-1 mAbの投与が必要な患者は、ミスマッチ修復（dMMR）タンパク質を欠くか、マイクロサテライト不安定性（MSI-H）が高い腫瘍も有していました。

研究活動の活発化が世界の転移性大腸がん市場の成長を牽引

2023年5月、武田薬品とHUTCHMED（China）Limitedは、すでに治療を受けている転移性大腸がん（CRC）成人患者に対する治療薬として、VEGFR-1、-2、-3の高活性かつ選択的な阻害薬であるfruquintinibの新薬承認申請（NDA）について、FDAが優先審査を認めたと報告しました。

承認されれば、フルクインチニブは、既に治療を受けている転移性CRCに対して米国で承認された最初で唯一の3つのVEGF受容体それぞれに対する高選択的阻害剤となります。FDAは2023年11月30日を本申請のPDUFA（Prescription Drug User Fee Act：処方薬ユーザーフィー法）目標日に設定しました。

転移性大腸がん治療に伴う副作用が世界の転移性大腸がん市場の成長を妨げる

転移性大腸がん治療に伴う副作用が市場の成長を抑制しています。がん細胞は、化学療法が標的とする分裂の速い細胞のひとつです。がん細胞は健康な細胞にも影響を及ぼし、多くの副作用を引き起こす可能性があります。吐き気や嘔吐、疲労、脱毛、下痢や便秘、骨髄抑制（血球数の減少）、口内炎、神経障害（神経損傷）などは、mCRCの治療に用いられる化学療法の典型的な副作用です。

標的療法は、がんの発生に関与する特定の化学物質に集中的に作用します。転移性大腸がん（mCRC）に対する標的療法は、皮膚反応（発疹、乾燥）、高血圧（高血圧）、胃腸障害（下痢、吐き気）、疲労、肝酵素の異常、出血や血液凝固のリスク増加などの副作用を引き起こすことが多いです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 転移性大腸がん治療に対するFDA承認の増加
  • 抑制要因
    • 転移性大腸がんに伴う副作用
  • 機会
    • 研究活動の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 治療法別

• 化学療法
• 標的療法
• 免疫療法
• その他

第10章 薬剤クラス別

• 抗EGFR（上皮成長因子受容体）阻害薬
• 抗VEGF（血管内皮増殖因子）治療薬
• 抗HER2（ヒト上皮成長因子受容体2）治療薬
• 免疫チェックポイント阻害剤
• その他

第11章 エンドユーザー別

• 病院
• がんセンター
• 外来手術センター
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Amgen
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• EMD Serono
• Eli Lilly
• Genentech
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi
• Suzhou Zelgen Biopharmaceuticals
• Taiho Oncology

第15章 付録

Overview

Global Metastatic Colorectal Cancer Market reached US$ 3.4 billion in 2022 and is expected to reach US$ 4.8 billion by 2030 growing with a CAGR of 4.6% during the forecast period 2023-2030. The metastatic colorectal cancer market is driven by factors such as increasing incidence and prevalence, increased research and development activities, and government initiatives.

Genetic variables, interactions with the tumor microenvironment, and other external factors all play a role in colorectal metastasis. Three types of therapeutic treatments can be used to treat metastatic colorectal cancer (mCRC): systemic chemotherapy, targeted therapy, and immunotherapy.

Market Dynamics

The Increasing FDA Approval for Metastatic Colorectal Cancer Treatment is Driving the Global Metastatic Colorectal Cancer Market Growth

In January 2023, Tucatinib (Tukysa, Seagen Inc.) and trastuzumab received accelerated approval from the Food and Drug Administration for the treatment of RAS wild-type HER2-positive metastatic or unresectable colorectal cancer that has progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy. An open-label, multicenter experiment called MOUNTAINEER (NCT03043313) examined effectiveness in 84 patients.

Patients had treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) in the past for colorectal cancer that was HER2-positive, RAS wild-type, unresectable or metastatic. Patients who needed to get an anti-programmed cell death protein-1 mAb also had tumors that lacked mismatch repair (dMMR) proteins or had high microsatellite instability (MSI-H).

The Increasing Research Activities are Driving the Global Metastatic Colorectal Cancer Market Growth

In May 2023, Takeda and HUTCHMED (China) Limited reported that the FDA granted priority review of the New Drug Application (NDA) for fruquintinib, a highly potent and selective inhibitor of VEGFR-1, -2, and -3 for the treatment of adult patients with metastatic colorectal cancer (CRC) who have already received treatment.

If authorized, fruquintinib will be the first and only highly selective inhibitor of each of the three VEGF receptors authorized in the United States for metastatic CRC that has already received treatment. The FDA set November 30, 2023, as the Prescription Drug User Fee Act (PDUFA) goal date for this NDA.

Side Effects Associated with Metastatic Colorectal Cancer Therapy are Hampering the Global Metastatic Colorectal Cancer Market Growth

Side effects associated with metastatic colorectal cancer therapy restraining the market growth. Cancer cells are among the fast-dividing cells that chemotherapy treatments target. They can, impact healthy cells, resulting in a number of adverse consequences. Nausea and vomiting, fatigue, hair loss, diarrhea or constipation, bone marrow suppression (lowered blood cell counts), mouth sores, and neuropathy (nerve damage) are typical adverse effects of chemotherapy used to treat mCRC.

Targeted therapies concentrate on specific chemicals implicated in the development of cancer. Targeted therapy for metastatic colorectal cancer (mCRC) frequently causes side effects such as skin reactions (rash, dryness), hypertension (high blood pressure), gastrointestinal problems (diarrhea, nausea), fatigue, abnormalities in liver enzymes, and an increased risk of bleeding or blood clotting.

For more details on this report - Request for Sample

Segment Analysis

The global metastatic colorectal cancer market is segmented based on treatment, drug class, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 41.3% of the metastatic colorectal cancer market in 2022. As per the article published in the International Journal of Molecular Sciences in 2023, For mCRC, cytotoxic chemotherapy is still the go-to treatment option. The foundation of combination regimens is made up primarily of fluoropyrimidines.

First-line therapy for metastatic colorectal cancer (mCRC) involves chemotherapy, such as FOLFOX (fluorouracil, leucovorin, and oxaliplatin), FOLFIRI (fluorouracil, leucovorin, and irinotecan), or FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan), either alone or in combination with.

Geographical Penetration

North America Holds a Dominant Position in the Global Metastatic Colorectal Cancer Market

North America is estimated to hold around 39.6% of the total market share in 2023. In September 2022, for patients with metastatic colon cancer for whom traditional therapy is no longer effective, a new phase 2 clinical trial directed by Robert Lentz, MD, a member of the University of Colorado Cancer Centre, may provide hope. In the United States, colorectal cancer is the third most prevalent and third most lethal cancer in both men and women. Furthermore, there are not many viable therapeutic alternatives available once chemotherapy and biological therapy cease to be successful in patients.

The issue is exacerbated by the fact that around 95% of colorectal cancer patients do not respond to immune treatment medications that have already received approval. In order to extend these patients' lives, they must be finding a means to trigger an anti-tumor immune response.

Competitive Landscape

The major global players in the market include: Amgen, EMD Serono, Eli Lilly, Genentech, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Suzhou Zelgen Biopharmaceuticals, and Taiho Oncology among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the metastatic colorectal cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. For cancer treatments to advance, clinical trials are necessary. As a result of the disagreement, new treatments for mCRC may take longer to develop, enrolment of new patients may be delayed, and proper data collecting may be hampered. Infrastructure and healthcare facilities may be destroyed or overburdened during a conflict. This might make it more difficult to give mCRC patients supportive care and specialized cancer therapies.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the metastatic colorectal cancer market to improve various aspects of data analysis. To find prospective treatment candidates and molecular targets for metastatic colorectal cancer, AI is utilized in drug discovery to analyze complicated biological and genomic data. By foreseeing potential drug interactions with certain tumor mutations, it can quicken the drug development process.

By Treatment

• Chemotherapy
• Targeted Therapies
• Immunotherapies
• Monotherapy and Combination Therapy
• Others

By Drug class

• Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• Immune Checkpoint Inhibitors
• Others

By End-user

• Hospitals
• Cancer Centers
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. reported that the U.S. Food and Drug Administration approved LONSURF (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the therapy of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Why Purchase the Report?

• To visualize the global metastatic colorectal cancer market segmentation based on the treatment, drug class, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of metastatic colorectal cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global metastatic colorectal cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment
• 3.2. Snippet by Drug Class
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising FDA approval for Metastatic Colorectal Cancer Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with Metastatic Colorectal Cancer
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing research activities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.1.2. Market Attractiveness Index, By Treatment
• 9.2. Chemotherapy*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Targeted Therapies
• 9.4. Immunotherapies
• 9.5. Others

10. By Drug Class

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.1.2. Market Attractiveness Index, By Drug Class
• 10.2. Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• 10.4. Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• 10.5. Immune Checkpoint Inhibitors
• 10.6. Others

11. By End-user

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Hospitals*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Cancer Centers
• 11.4. Ambulatory Surgical Centers
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Amgen*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. EMD Serono
• 14.3. Eli Lilly
• 14.4. Genentech
• 14.5. Novartis AG
• 14.6. Pfizer Inc.
• 14.7. F. Hoffmann-La Roche Ltd
• 14.8. Sanofi
• 14.9. Suzhou Zelgen Biopharmaceuticals
• 14.10. Taiho Oncology

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us